HIV and tuberculosis - Science and implementation to turn the tide and reduce deaths

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  Harries, Anthony D ^a,b   Lawn, Stephen D ^b,c   Getahun, Haileyesus ^d   Zachariah, Rony ^e   Havlir, Diane V ^f  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; HIV; Intensified case finding; Isoniazid preventive therapy; Mortality; Tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BCG VACCINE; COTRIMOXAZOLE; ISONIAZID; ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

ANTIMICROBIAL THERAPY; BCG VACCINATION; CD4 LYMPHOCYTE COUNT; CHILDHOOD DISEASE; EARLY DIAGNOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; NUCLEIC ACID AMPLIFICATION; POINT OF CARE TESTING; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; WEIGHT REDUCTION; CHEMOPROPHYLAXIS; INFECTION CONTROL; MASS SCREENING; METHODOLOGY; TIME;

ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CHEMOPREVENTION; COMMUNICABLE DISEASE CONTROL; HIV INFECTIONS; HUMANS; MASS SCREENING; TIME FACTORS; TUBERCULOSIS;

EID: 84867444399     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17396     Document Type: Review

References (108)

1. World Health Organization. Global tuberculosis control: WHO Report 2011. Geva, Switzerland: WHO; 2011. WHO/HTM/TB/2011.16.
2. World Health Organization, UNAIDS, UNICEF. Global HIV/AIDS Response. Epidemic update and health sector progress towards Universal Access. Progress Report 2011. Geneva, Switzerland: World Health Organization.
3. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;2:1897-908.
4. Lucas SB, De Cock KM, Hounnou A, Peacock C, Diomande M, Honde M, et al. Contribution of tuberculosis to slim disease in Africa. BMJ. 1994;2: 1531-3.
5. Rana FS, Hawken MP, Mwachari C, Bhatt SM, Abdullah F, Nganga LW, et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2000;2:23-9.
6. Ansari NA, Kombe AH, Kenyon TA, Hone NM, Tappero JW, Nyirenda ST, et al. Pathology and causes of death in a group of 128 predominately HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis. 2002;2:55-63.
7. Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu Natal, South Africa: a post-mortem study. PLoS Med. 2010;7:e1000296.
8. Wong EB, Omar T, Setlhako G, Osih R, Murdoch D, Martinson N, et al. Causes of death in ART treated adults: a post-mortem study from Johannesburg, South Africa. Abstracts of the XVIII International AIDS Conference, International AIDS Society, Vienna, Austria, 2010. Abstract WEPE0154.2010.
9. Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis. 2001;2:1000-5.
10. Diul MY, Maher D, Harries AD. Tuberculosis case fatality rates in HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15:143-52.
11. Ackah AN, Coulibaly D, Digbeu H, Diallo K, Vetter KM, Coulibaly IM, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet. 1995;2:607-10.
12. Perriens JH, St. Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995;2:779-84.
13. Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, Chimzizi R, et al. The HIV-associated tuberculosis epidemic - when will we act? Lancet. 2010;2:1906-19.
14. World Health Organization. WHO policy on collaborative TB/HIV activities. Guidelines for national programmes and other stakeholders. WHO/HTM/TB/ 2012.1 and WHO/HIV/2012.1 [Internet]. Geneva, Switzerland: WHO; 2012 [cited 2012 Mar 2]. Available from: http://whqlibdoc.who.int/publications/ 2012/9789241503006- eng.pdf
15. World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva: WHO; 2004. WHO/HTM/TB/2004. 330. WHO/HTM/HIV/ 2004.1.
16. World Health Organization. World Tuberculosis Day 2012: joint message from the Directors of WHO HIV and Stop TB Partnership. Geneva, Switzerland: WHO; 2012.
17. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral therapy for prevention of HIV-associated tuberculosis in developing countries: a systematic review and meta-analysis. PLoS Med. 2012;9: e1001270.
18. Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis. 2011;2:571-81.
19. Gupta A, Wood R, Kaplan R, Bekker L-G, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 2012;7:e34156.
20. Zachariah R, Bemelmans M, Akesson A, Gomani P, Phiri K, Isake B, et al. Reduced tuberculosis case notification associated with scaling up antiretroviral treatment in rural Malawi. Int J Tuberc Lung Dis. 2011;2:933-7.
21. Middelkoop K, Bekker L-G, Myer L, Johnson LF, Kloos M, Morrow C, et al. Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr. 2011;2:263-9.
22. Severe P, Juste MAJ, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;2:257-65.
23. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 Revision. Geneva, Switzerland: WHO; 2010.
24. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al.; for the HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;2:493-505.
25. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
26. Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, Dye C. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Nat Acad Sci U S A. 2010;2:19485-9.
27. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, et al.; on behalf of the ART in Prevention of HIV and TB Research Writing Group. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;2:446-69.
28. Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet. 2011;2:282-4.
29. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst Rev. 2010:CD000171.
30. WHO, UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV [Internet]. WHO/TB/98.255. UNAIDS/98.34. Geneva, Switzerland: WHO; 1998 [cited 2012 Mar 30]. Available from: http:// whqlibdoc.who.int/hq/1998/WHO-TB-98.255.pdf
31. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings [Internet]. Geneva, Switzerland: WHO; 2011 [cited 2012 July 15]. Available from: http://whqlibdoc.who.int/pubblications/1/ 9789241500708-eng.pdf
32. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebocontrolled trial. Lancet. 2011;2:1588-98.
33. Samandari T, Agizew T, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, et al. TB incidence increase after cessation of 36 months isoniazid prophylaxis in HIV-adults: Botswana. 19th Conference on Retroviruses and Opportunistic Infections 2012, Session 41, Oral Abstracts, Number #147.
34. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BG, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;2:1441-8.
35. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;2:631-6.
36. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIVassociated tuberculosis in settings with limited-health-care resources. Lancet Infect Dis. 2010;2:489-98.
37. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, et al. Development of a standardised screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data metaanalysis of observational studies. PLoS Med. 2011;8:e1000391.
38. WHO, UNAIDS. A guide to monitoring and evaluation for collaborative TB/HIV activities. WHO/HTM/TB/2009.414. WHO/HTM/HIV/09.01. Geneva, Switzerland: World Health Organization; 2009.
39. Gupta A, Chandrasekhar A, Gupte N, Patil S, Bhosale R, Sambarey P, et al.; the Medical College-Johns Hopkins University Study Group. Symptom screening among HIV-infected pregnant women is acceptable and has high negative predictive value for active tuberculosis. Clin Infect Dis. 2011;2:1015-8.
40. Kranzer K, Houben RMGJ, Bekker LG, Wood R, Lawn SD. Yield of HIVassociated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis. 2010;2: 93-102.
41. Oni T, Burke R, Tsekela R, Bangani N, Seldon R, Gideon HP, et al.High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax. 2011;2:669-73.
42. Lawn SD, Kerkhoff AD, Wood R. Progression of subclinical culture-positive tuberculosis to symptomatic disease in HIV-infected individuals. AIDS. 2011;2:2190-1.
43. Reid MJA, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis. 2009;2:173-84.
44. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis. 2011;204:S1159-67.
45. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis. 2010;2:1295-302.
46. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;2:1005-15.
47. Lawn SD, Zumla AI. Diagnosis of extrapulmonary tuberculosis using the Xpert MTB/RIF assay. Exp Rev Anti-Infect Ther. 2012;2:631-5.
48. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;2:1495-505.
49. Lawn SD, Kerkhoff AD, Wood R. Location of Xpert MTB/RIF in centralized laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis. 2012;2:701.
50. Lawn SD, Kerkhoff AD, Vogt M,Wood R. Diagnostic accuracy of a low-cost, urine antigen, pointof-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;12:201-9.
51. Dorman S, Manabe Y, Nicol M, Nakiyingi L, Moodley M, Zemanay W, et al. Accuracy of determine TB-LAM lateral flow test for diagnosis of TB in HIV- adults: interim results from a multicenter study. 19th Conference on Retroviruses and Opportunistic Infections 2012, Session 41, Oral Abstracts, Number #149 aLB.
52. Lawn SD, Ayles H, Egwaga S, Williams B, Mukadi YD, Santos-Filho ED, et al. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis. 2011;2:287-95.
53. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related among children, adolescents and adults. Recommendations for a public health approach [Internet]. Geneva, Switzerland: WHO; 2006 [cited 2010 Feb 6]. Available from: http://www.who.int/hiv/pub/guidelines/ctx/en/ index.html
54. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet. 1999;2:1469-74.
55. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A; for the UNZA-UCLMS Project LUCOT Collaboration. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomized clinical trial. BMJ. 2008;337:a257. doi:10:1136/bmj.a257(1-7).
56. Zachariah R, Spielmann M-P, Chinji C, Gomani P, Arendt V, Hargreaves NJ, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS. 2003;2:1053-61.
57. Mwaungulu FBD, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyongoloka H, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga district, Malawi. Bull World Health Organ. 2004;2:354-62.
58. Grimwade K, Sturm W, Nunn AJ, Mbatha D, Zungu D, Gilks CF. Effectiveness of cotrimoxazole on mortality in adults with tuberculosis in rural South Africa. AIDS. 2005;2:163-8.
59. Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, Eiger O, et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr. 2007;2:56-61.
60. Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, Reid A, et al. Daily cotrimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet. 2010;2:1278-86.
61. Suthar AB, Granich R, Mermin J, Van Rie A. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ. 2012;2:128-38C.
62. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;2: 1605-12.
63. Lawn SD, Kranzer K,Wood R. Antiretroviral therapy for control of the HIVassociated tuberculosis epidemic in resource-limited settings. Clin Chest Med. 2009;2:685-99.
64. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and metaanalysis. Clin Infect Dis. 2010;2:1288-99.
65. WHO, UNAIDS. Guidance on provider-initiated HIV testing and counseling in health facilities. Geneva, Switzerland: WHO; 2007.
66. Odhiambo J, Kizitu W, Njoroge A, Wambua N, Nganga L, Mburu M, et al. Provider initiated HIV testing and counselling for TB patients and suspects in Nairobi, Kenya. Int J Tuberc Lung Dis. 2008;12(Suppl 1):S63-8.
67. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa (State of the ART). Int J Tuberc Lung Dis. 2009;13:6-16.
68. Kyeyune R, den Boon S, Cattamanchi A, Davis JL,Worodria W, Yoo SD, et al. Causes of early mortality in HIV-infected TB suspects in an East African Referral Hospital. J Acquir Immune Defic Syndr. 2010;2:446-50.
69. Porskrog A, Bjerregaard-Andersen M, Oliveira I, Joaquim LC, Camara C, Andersen PL, et al. Enhanced tuberculosis identification through 1-month follow-up of smear-negative tuberculosis suspects. Int J Tuberc Lung Dis. 2011;2:459-64.
70. Dimairo M, MacPherson P, Bandason T, Zezai A, Munyati SS, Butterworth AE, et al. The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: a 12 month cohort study in Harare, Zimbabwe. PLoS One. 2010;5:e11849.
71. MacPherson P, Dimairo M, Bandason T, Zezai A, Munyati SS, Butterworth AE, et al. Risk factors for mortality in smear-negative tuberculosis suspects: a cohort study in Harare, Zimbabwe. Int J Tuberc Lung Dis. 2011;2:1390-6.
72. Karim SSA, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;2:697-706.
73. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. for the CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;2:1471-81.
74. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al.; for the AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;2:1482-91.
75. Karim SSA, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;2:1492-501.
76. Degu WA, Lindquist L, Aderaye G, Aklillu E, Wold AH, Ali GY, et al. Randomized clinical trial to determine efficacy and safety of ART 1 week after TB therapy in patients with CD4 countsB200 cells/mL. 19th Conference on Retroviruses and Opportunistic Infections 2012, Session 41, Oral Abstracts, Number #144.
77. Luetkemeyer A, Kendall M, Nyirenda M, Wu X, Ive P, Andersen J, et al.; A5221 Study Team. Severity and timing of paradoxical TB-IRIS in a 48-week multicenter randomized trial of immediate vs early ART in patients with CD4B250 cells/mL starting TB Treatment: A5221 STRIDE Study. 19th Conference on Retroviruses and Opportunistic Infections 2012, Session 41, Oral Abstracts, Number #145.
78. Torok ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis. 2011;2:1374-83.
79. Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, Renaud-Thery F, et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can abutin fill the breach? Int J Tuberc Lung Dis. 2012;2:6-15.
80. Wells CD, Cegielski JP, Nelson LJ, Lasrerson KF, Holtz TH, Finlay A, et al. HIV infection and multidrug-resistant tuberculosis - the perfect storm. J Infect Dis. 2007;196:S86-107.
81. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Laloo U, et al. Extensively drug resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;2:1575-80.
82. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, et al. Tugela Ferry Care and Research (TF-CARES) Collaboration. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;2:80-6.
83. Palacios E, Franke M, Munoz M, Hurtado R, Dallman R, Chalco K, et al. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis. 2012;2:348-54.
84. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drugresistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;2:1798-807.
85. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 Update. Geneva, Switzerland: WHO; 2011. WHO/HTM/TB/2011.6
86. Scano F, Vitoria M, Burman W, Harries AD, Gilks CF, Havlir D. Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis. 2008;2:1370-5.
87. Getahun H, Sculier D, Sismanidis C, Grzemska M, Raviglione M. Prevention, diagnosis, and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health services. J Infect Dis. 2012;S205(Suppl 2):S16-27.
88. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, et al. UNZA-UCLMS Project Paediatric Post-mortem Study Group. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet. 2002;2:985-90.
89. Ansari NA, Kombe AH, Kenyon TA, Mazhani L, Binkin N, Tappero JW, et al. Pathology and causes of death in a series of human immunodeficiency viruspositive and -negative pediatric referral hospital admissions in Botswana. Pediatr Infect Dis J. 2003;2:43-7.
90. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO; 2010 Revision.
91. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al.; for the CHER Study Team. Early antiretroviral therapy and mortality among HIVinfected infants. N Eng J Med. 2008;2:2233-44.
92. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al.; for the P1041 Study Team. Primary isoniazid prophylaxis against tuberculosis in HIVexposed children. N Eng J Med. 2011;2:21-31.
93. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;2:136.
94. Nicol MP,Workman L, Isaacs W, Munro J, Black F, Eley B, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis. 2011;2:819-24.
95. Ligthelm LJ, Nicol MP, Hoek KG, Jacobson R, van Helden PD, Marais BJ, et al. Xpert MTB/RIF for rapid diagnosis of tuberculosis lymphadenitis from fine-needle-aspiration biopsy specimens. J Clin Microbiol. 2011;2:3967-70.
96. Lawn SD, Wood R. Timing of antiretroviral therapy for HIV-1-associated tuberculosis. N Engl J Med. 2012;2:474.
97. Howard AA, El-Sadr WM. Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. Clin Infect Dis. 2010;50(S3):S238-44.
98. Choko AT, Desmond N, Webb EL, Chavula K, Napierala-Mavedzenge S, Gaydos CA, et al. The uptake and accuracy of oral kits for HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. PLoS Med. 2011;8:e1001102.
99. Smart T. An intensive household counselling intervention reduces the burden of TB in ZAMSTAR study. HIV and AIDS Treatment in Practice. 2011;Issue 184:3-4.
100. Smart T. The implications of ZAMSTAR for research and policy. HIV and AIDS Treatment in Practice. 2011;Issue 184:5-8.
101. Ayles H.; the ZAMSTAR Study Team. A household-based HIV and TB intervention increases HIV testing in households and reduces prevalence of TB at the community level: The ZAMSTAR Community Randomized Trial. 19th Conference on Retroviruses and Opportunistic Infections 2012, Session 41, Oral Abstracts, Number #149 bLB.
102. Corbett EL, Bandason T, Duong T, Dauya B, Makamure B, Churchyard GJ, et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet. 2010;2:1244-53.
103. Churchyard G, Fielding K, Lewis J, Coetzee L, Corbett E, Godfrey-Faussett P, et al.; on behalf of the Thibela TB Team. Community-wide isoniazid preventive therapy does not improve TB control among gold miners: the Thibela TB Study, South Africa. 19th Conference on Retroviruses and Opportunistic Infections 2012, Session 41, Oral Abstracts, Number #150aLB.
104. Fielding K, Grant A, Lewis J, Hayes R, Churchyard G. Individual-level effect of isoniazid preventive therapy on risk of TB: The Thibela TB study. 19th Conference on Retroviruses and Opportunistic Infections 2012, Session 41, Oral Abstracts, Number #150bLB.
105. Kranzer K, Lawn SD, Meyer-Rath G, Vassall A, Raditlhalo E, Govindasamy D, et al. Feasibility, yield and cost of active tuberculosis case finding linked to a mobile HIV testing service in Cape Town, South Africa. Tuberculosis control in a South African community with high HIV prevalence: the role of intensified case-finding and antiretroviral therapy. PLoS Med. Forthcoming 2012.
106. Gandhi N, Moll AP, Lalloo U, Pawinski R, Zeller K, Moodley P, et al.; on behalf of the Tugela Ferry Care and Research (TFCaRes) Collaboration. Successful integration of tuberculosis and HIV treatment in rural South Africa: The Sizonq'oba Study. J Acquir Immune Defic Syndr. 2009;2:37-43.
107. UNAIDS. 2010 World AIDS Day Message. Zero new HIV infections. Zero discrimination. Zero AIDS-related deaths. 1 December 2010.
108. Drasar B. Editorial. Int Health. 2009;1:1-2.